Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus

Thota, Prashanthi N.; Kistangari, Gaurav; Singh, Prabhdeep; Cummings, Linda C.; Hajifathalian, Kaveh; López, Rocío; Sanaka, Madhusudhan R.

doi:10.1007/s10620-015-3823-5

Cited by 8 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with Barrett's esophagus, no association was found between circulating 25(OH)D levels and incidence of esophageal adenocarcinoma despite a high prevalence of vitamin D deficiency (23.6%) or insufficiency (34.7%) 81 . However, in another study, patients receiving vitamin D supplements postoperatively for esophageal cancer had a longer disease‐free period, although there was no difference in overall survival 82 …”

Section: Vitamin Dmentioning

confidence: 99%

Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?

Marian

2017

Nut in Clin Prac

View full text Add to dashboard Cite

Following a cancer diagnosis, dietary supplements are reportedly used by 20%-80% of individuals. Supplements are most commonly used by breast cancer survivors, followed by patients with prostate, colorectal, and lung cancers, which is not surprising since these are the most common types of cancer diagnosed in adults. Reasons cited for such use include improving quality of life, reducing symptoms related to treatment and/or the disease process, and recommendation from medical practitioners; family and friends may also be an influence. However, controversy surrounds the use of dietary supplements, particularly during treatment-specifically, whether supplements affect treatment efficacy is unknown. This article discusses the evidence related to common dietary supplements used to prevent cancer or a recurrence.

show abstract

Section: Vitamin Dmentioning

confidence: 99%

Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?

Marian

2017

Nut in Clin Prac

View full text Add to dashboard Cite

show abstract

“…Finally, a BE registry cohort study found no association between circulating 25(OH)D concentration and risk of prevalent or incident dysplasia or EAC in BE patients (36). The findings from the present Mendelian randomization study provide further evidence that 25(OH)D concentration is not associated with the risk of BE or EAC.…”

Section: Discussionmentioning

confidence: 40%

“…Conversely, a case-control study in Australia reported a decreased risk of EAC with higher ultraviolet B exposure although, even if a true finding, this is not necessarily due to vitamin D (9). While there is some evidence that BE patients are often vitamin D insufficient (35,36), studies to date have found no association between vitamin D intake and the risk of BE (10), and vitamin D supplementation has been shown to have no effect on risk of neoplastic progression in BE patients (35).…”

Section: Discussionmentioning

confidence: 98%

No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study

Dong

Gharahkhani

Chow

et al. 2019

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background Epidemiological studies on circulating concentrations of 25 hydroxy vitamin D (25(OH)D) and risks of esophageal adenocarcinoma (EAC) have shown conflicting results. Here we conducted a Mendelian randomization study to determine the associations between circulating concentrations of 25 hydroxy vitamin D (25(OH)D) and risks of EAC and its precursor, Barrett's esophagus (BE). MethodsWe conducted a Mendelian randomization study using a two-sample (summary data) approach.Six single-nucleotide polymorphisms (SNPs) (rs3755967, rs10741657, rs12785878, rs10745742, rs8018720 and rs17216707) associated with circulating 25(OH)D concentrations were used as instrumental variables. Data from 6,167 BE patients, 4,112 EAC patients and 17,159 control participants were from studies participating in the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), as well as studies from Bonn, Germany, and Cambridge and Oxford, United Kingdom. Analyses were performed separately for BE and EAC. ResultsOverall, we found no evidence for an association between genetically estimated 25(OH)D concentration and the risk of BE or EAC. The odds ratio (OR) per 20 nmol/L increase in genetically estimated 25(OH)D concentration for BE risk estimated by combining the individual SNP association using inverse variance weighting was 1.21 (95% confidence interval, CI, 0.77-1.92; P = 0.41). The OR for EAC risk estimated by combining the individual SNP association using inverse variance weighting was 0.68 (95% CI, 0.39-1.19; P = 0.18). ConclusionsThis Mendelian randomization study found that low genetically estimated 25(OH)D concentrations were not associated with the risks of BE or EAC.

show abstract

“…These results are similar to recent findings by Thota et al reporting a mean 25-OH vitamin D level of 72 nmol/L (29 ng/mL) in a registry of 429 BE patients. [ 47 ] In that study, there was no association between vitamin D status and incidence or prevalence of HGD/EAC. An older prospective study demonstrated an association between low vitamin D levels and increased risk for esophageal cancer, not further delineated by histologic subtype.…”

Section: Discussionmentioning

confidence: 77%

A nonrandomized trial of vitamin D supplementation for Barrett’s esophagus

Cummings

Thota

Willis³

et al. 2017

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundVitamin D deficiency may increase esophageal cancer risk. Vitamin D affects genes regulating proliferation, apoptosis, and differentiation and induces the tumor suppressor 15-hydroxyprostaglandin dehydrogenase (PGDH) in other cancers. This nonrandomized interventional study assessed effects of vitamin D supplementation in Barrett’s esophagus (BE). We hypothesized that vitamin D supplementation may have beneficial effects on gene expression including 15-PGDH in BE.MethodsBE subjects with low grade or no dysplasia received vitamin D3 (cholecalciferol) 50,000 international units weekly plus a proton pump inhibitor for 12 weeks. Esophageal biopsies from normal plus metaplastic BE epithelium and blood samples were obtained before and after vitamin D supplementation. Serum 25-hydroxyvitamin D was measured to characterize vitamin D status. Esophageal gene expression was assessed using microarrays.Results18 study subjects were evaluated. The baseline mean serum 25-hydroxyvitamin D level was 27 ng/mL (normal ≥30 ng/mL). After vitamin D supplementation, 25-hydroxyvitamin D levels rose significantly (median increase of 31.6 ng/mL, p<0.001). There were no significant changes in gene expression from esophageal squamous or Barrett’s epithelium including 15-PGDH after supplementation.ConclusionBE subjects were vitamin D insufficient. Despite improved vitamin D status with supplementation, no significant alterations in gene expression profiles were noted. If vitamin D supplementation benefits BE, a longer duration or higher dose of supplementation may be needed.

show abstract

Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus

Abstract: Serum 25(OH)D levels were low in 58.3 % of our BE cohort. There was no association between 25(OH)D levels and prevalence or incidence of HGD/EAC in patients with BE. Further long-term studies are needed to study the association between vitamin D status and progression of dysplasia in BE.

Cited by 8 publications

References 22 publications

Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?

Dietary Supplements Commonly Used by Cancer Survivors: Are There Any Benefits?

No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study

A nonrandomized trial of vitamin D supplementation for Barrett’s esophagus

Contact Info

Product

Resources

About